Pages

Tuesday, July 19, 2011

DUAL LAYER L-DOPA CLINICAL TRIAL RESULTS

16th July 2011 - New research

Movement Disorders [2011] Jul 13 [Epub ahead of print] (R.A.Hauser, A.L.Ellenbogen, L.V.Metman, A.Hsu, M.J. O'Connell, N.B.Modi, H.M.Yao, S.H.Kell, S.K.Gupta)
L-dopa combined with carbidopa usually comes in two different forms : either the immediate release version (such as Regular Sinemet), which satisfies the immediate need for L-dopa, or the controlled release version (such as Sinemet CR), which avoids the excessive effects of L-dopa by spreading out the effects of the L-dopa over time.

Dual layer L-dopa combines the two types of L-dopa and carbidopa - an immediate release form and a controlled release form, all in the same tablet. Dual layer L-dopa is consequently being developed as a possible replacement for Sinemet and Sinemet CR. Dual layer L-dopa (IPX054) was shown to be slightly more effective than conventional forms of L-dopa, despite having to be taken only twice a day instead of throughout the day. Dual layer L-dopa (IPX066) increased L-dopa levels at the same rate as immediate release L-dopa and carbidopa, and also provided more sustained L-dopa concentrations. It also substantially reduced the variability in plasma concentrations of L-dopa, despite being taken less often.

No comments:

Post a Comment